Humacyte (HUMA) vs Tonix Pharmaceuticals (TNXP)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Tonix Pharmaceuticals (TNXP) has outperformed Humacyte (HUMA) over the past year, losing 67.2% versus a loss of 71.3%. Over five years, HUMA leads with a -95.4% price change compared with -100.0% for TNXP. Humacyte is the larger company by market cap ($131.2 million vs $129.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | HUMA | TNXP |
|---|---|---|
| Share price | $0.4723 | $7.55 |
| Market cap | $131.20M | $129.49M |
| 1-day change | -1.19% | -1.88% |
| YTD return | -50.85% | -51.66% |
| 1-year return | -71.29% | -67.17% |
| 5-year return | -95.38% | -100.00% |
| EPS (TTM) | $-0.51 | $-13.06 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.90 | $23.25 |
| 52-week low | $0.46 | $7.42 |
| Distance from 52-week high | -75.08% | -67.53% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +245.12% | +489.40% |
| Average volume | 6.35M | 537.24K |
| Shares outstanding | 277.80M | 17.15M |
| Employees | 184 | 142 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Humacyte
HUMA stock →Humacyte, Inc., together with its subsidiaries, engages in the development and manufacture of off-the-shelf, implantable, and bioengineered human tissues for the treatment of diseases and conditions across a range of anatomic locations in multiple therapeutic areas. The company using its proprietary and scientific technology platform to engineer and manufacture human acellular vessels (HAVs) to be implanted into patient without inducing a foreign body response or leading to immune rejection.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 184 employees
About Tonix Pharmaceuticals
TNXP stock →Tonix Pharmaceuticals Holding Corp., a fully integrated biopharmaceutical company, develops and commercializes therapies for central nervous system (CNS) disorders, immunology and immuno-oncology, infectious diseases, and rare diseases in the United States. The company offers TONMYA, a cyclobenzaprine HCl sublingual tablet for the treatment of fibromyalgia.
Health Care · Biotechnology: Pharmaceutical Preparations · 142 employees
HUMA vs TNXP FAQ
Which is bigger, Humacyte or Tonix Pharmaceuticals?
Humacyte (HUMA) is larger, with a market capitalization of $131.20M compared with $129.49M for Tonix Pharmaceuticals (TNXP).
Which stock has performed better over the past year, HUMA or TNXP?
TNXP returned -67.17% over the past 12 months, compared with -71.29% for HUMA (price return, excluding dividends). Past performance does not predict future results.
Are Humacyte and Tonix Pharmaceuticals in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for Humacyte and Biotechnology: Pharmaceutical Preparations for Tonix Pharmaceuticals.